28 December, 1999

Clinical Chemistry and Laboratory Medicine
attn. Dr. Marek H. Dominiczak
Walter de Gruyter GmbH & Co. KG
Postfach 30 34 21
D-10728 Berlin
Germany

Dear Dr. Donimiczak:

Thank you for your letter concerning my paper. Enclosed are revised four copies of my article entitled “Macro creatine kinase type 1: a clinically significant marker?” It has been modified in accordance with the referee’s comment. The revision was done in the second paragraph, which was underlined as follows.

A 70-year-old man had muscle ache in the vicinity of the four limbs for some years. He had neither a past history of diagnosed musculoskeletal disease such as myositis, heart disease, autoimmune disease, malignancies or a family history of such diseases. Although he had received occasional treatment with non-steroidal anti-inflammatory drugs, satisfactory efficacy on his pain had not been obtained. His other physical findings were all normal. A serum CK rise (589IU/L; reference interval 50-210 IU/L) was revealed in ambulatory treatment, necessitating a CK isoenzyme test, which yielded an abnormal band of CK type 1 (between MB and MM bands) in electrophoresis. At the isoenzyme test, the determinations of CK-BB, MB and MM were 0, 16 and 525 IU/L, respectively. Three autoimmune antibody tests (rheumatoid factor, anti-Jo1 and anti-DNA) yielded negative results and other biochemical parameters were all within reference ranges. Subsequently, an abnormal band of CK type 1 and a slight increase of total CK (220-280IU/L) has persisted along with his chronic pain for some months. However, he has refused further examinations such as electromyogram and muscle biopsy, and a referral to specialists to the present time.

Sincerely yours,

Kazuo Inoue, MD
The corresponding author
Towa Clinic, Department of Community and Family Medicine
Jichi Medical School
468 Showa, Towa, Hata, Kochi, 786-0511 Japan
Phone: +81-880-28-5523
Fax: +81-880-28-5158
E-mail: ikazu@ps.inforyoma.or.jp